Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ: ALLO )

2.090 +0.140 (+7.18%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,810,945
Open 1.940
Bid (Size) 2.060 (8)
Ask (Size) 2.080 (30)
Prev. Close 1.950
Today's Range 1.910 - 2.100
52wk Range 1.780 - 5.775
Shares Outstanding 142,183,418
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
From Allogene Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-42.27%
-42.27%
1 Month
-8.33%
-8.33%
3 Month
-21.72%
-21.72%
6 Month
-12.92%
-12.92%
1 Year
-32.14%
-32.14%

More News

Read More
Allogene Therapeutics Announces Participation in December Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics
Via Benzinga
Analyst Ratings For Allogene Therapeutics
Via Benzinga
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in November Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors
From Artiva Biotherapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
7 Biotech Stocks to Buy for Their Game-Changing Potential
Via InvestorPlace
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
Via Benzinga
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
From Allogene Therapeutics, Inc.
Via GlobeNewswire
If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 Names
Via InvestorPlace
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Why James Hardie Industries Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.